Fig. 1: Schematic representation of the pharmacokinetic and electrophysiology study design. | Cell Death & Disease

Fig. 1: Schematic representation of the pharmacokinetic and electrophysiology study design.

From: A potassium channel agonist protects hearing function and promotes outer hair cell survival in a mouse model for age-related hearing loss

Fig. 1

a Schematic representation of the pharmacokinetic study design. Cochlear perilymph and tissue were sampled after a single administration of 0.6% or 6.0% w/v ACOU085 formulation via transtympanic injection into both ears of SAMP8 mice. Samples were collected for the timepoints 0.25, 7, 14, 21, and 28 days post-administration (postA). Concentrations of ACOU085 in cochlear perilymph and tissue were determined by liquid chromatography and mass spectrometry. b Schematic representation of the electrophysiology study design. The effect of repeated unilateral administrations via transtympanic injection of ACOU085 versus contralateral vehicle control was investigated in the SAMP8 mouse model for two dose groups, 0.6% or 6.0% w/v ACOU085, in a within-subject design. Auditory function was assessed at 1-month intervals from the age of 45 days (pre-treatment, preT) to 135 days (3-months post-treatment, postT) by determining auditory brainstem response (ABR) thresholds. After termination, mice were sacrificed and their cochleae were extracted for cochlear whole-mount analysis.

Back to article page